Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management

Depression is a major neuropsychiatric disorder common in patients with rheumatological conditions including spondyloarthritis (SpA). It is associated with higher disease activity, functional impairment, poor treatment response and quality of life in patients with musculoskeletal disorders. Using an...

Full description

Bibliographic Details
Main Authors: Joel T. Parkinson, Éimear M. Foley, Deepak R. Jadon, Golam M. Khandaker
Format: Article
Language:English
Published: SAGE Publishing 2020-10-01
Series:Therapeutic Advances in Musculoskeletal Disease
Online Access:https://doi.org/10.1177/1759720X20970028
id doaj-1d6e45960fbc4e0897ff4ba3b3ddfae8
record_format Article
spelling doaj-1d6e45960fbc4e0897ff4ba3b3ddfae82021-07-14T11:04:01ZengSAGE PublishingTherapeutic Advances in Musculoskeletal Disease1759-72182020-10-011210.1177/1759720X20970028Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and managementJoel T. ParkinsonÉimear M. FoleyDeepak R. JadonGolam M. KhandakerDepression is a major neuropsychiatric disorder common in patients with rheumatological conditions including spondyloarthritis (SpA). It is associated with higher disease activity, functional impairment, poor treatment response and quality of life in patients with musculoskeletal disorders. Using ankylosing spondylitis (AS) and psoriatic arthritis (PsA) as examples, we have reviewed the evidence regarding the burden, risk factors, potential mechanisms and clinical management of depression in spondyloarthritis. The prevalence of depression is higher in patients with AS and PsA compared with the general population, with evidence of moderate/severe depression in about 15% of patients with AS or PsA. Mild depression is even more common and estimated to be present in about 40% of patients with AS. In addition to conventional risk factors such as stressful life events and socioeconomic deprivation, increased risk of depression in SpA may be associated with disease-related factors, such as disease activity, poor quality of life, fatigue, and sleep disturbances. Emerging evidence implicates inflammation in the aetiology of depression, which could also be a shared mechanism for depression and chronic inflammatory conditions such as AS and PsA. It is imperative for clinicians to actively assess and treat depression in SpA, as this could improve treatment adherence, quality of life, and overall long-term clinical and occupational outcomes. The use of validated tools can aid recognition and management of depression in rheumatology clinics. Management of depression in SpA, especially when to refer to specialist mental health services, are discussed.https://doi.org/10.1177/1759720X20970028
collection DOAJ
language English
format Article
sources DOAJ
author Joel T. Parkinson
Éimear M. Foley
Deepak R. Jadon
Golam M. Khandaker
spellingShingle Joel T. Parkinson
Éimear M. Foley
Deepak R. Jadon
Golam M. Khandaker
Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management
Therapeutic Advances in Musculoskeletal Disease
author_facet Joel T. Parkinson
Éimear M. Foley
Deepak R. Jadon
Golam M. Khandaker
author_sort Joel T. Parkinson
title Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management
title_short Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management
title_full Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management
title_fullStr Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management
title_full_unstemmed Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management
title_sort depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management
publisher SAGE Publishing
series Therapeutic Advances in Musculoskeletal Disease
issn 1759-7218
publishDate 2020-10-01
description Depression is a major neuropsychiatric disorder common in patients with rheumatological conditions including spondyloarthritis (SpA). It is associated with higher disease activity, functional impairment, poor treatment response and quality of life in patients with musculoskeletal disorders. Using ankylosing spondylitis (AS) and psoriatic arthritis (PsA) as examples, we have reviewed the evidence regarding the burden, risk factors, potential mechanisms and clinical management of depression in spondyloarthritis. The prevalence of depression is higher in patients with AS and PsA compared with the general population, with evidence of moderate/severe depression in about 15% of patients with AS or PsA. Mild depression is even more common and estimated to be present in about 40% of patients with AS. In addition to conventional risk factors such as stressful life events and socioeconomic deprivation, increased risk of depression in SpA may be associated with disease-related factors, such as disease activity, poor quality of life, fatigue, and sleep disturbances. Emerging evidence implicates inflammation in the aetiology of depression, which could also be a shared mechanism for depression and chronic inflammatory conditions such as AS and PsA. It is imperative for clinicians to actively assess and treat depression in SpA, as this could improve treatment adherence, quality of life, and overall long-term clinical and occupational outcomes. The use of validated tools can aid recognition and management of depression in rheumatology clinics. Management of depression in SpA, especially when to refer to specialist mental health services, are discussed.
url https://doi.org/10.1177/1759720X20970028
work_keys_str_mv AT joeltparkinson depressioninpatientswithspondyloarthritisprevalenceincidenceriskfactorsmechanismsandmanagement
AT eimearmfoley depressioninpatientswithspondyloarthritisprevalenceincidenceriskfactorsmechanismsandmanagement
AT deepakrjadon depressioninpatientswithspondyloarthritisprevalenceincidenceriskfactorsmechanismsandmanagement
AT golammkhandaker depressioninpatientswithspondyloarthritisprevalenceincidenceriskfactorsmechanismsandmanagement
_version_ 1721303045589958656